The duo closed up, respectively, 40% and ~58% higher following Tuesday's after the market close release of phase 3 data for Alzheimer's candidate lecanemab.
That helped boost the fortune of other Alzheimer's therapy developers. The best performer of the day was Acumen Pharmaceuticals (ABOS), which ended the day up ~104%. The company has the anti-amyloid-beta oligomer monoclonal antibody ACU193, currently in phase 1.
The second best Alzheimer's-related developer of the day was Prothena Corp. (PRTA), closing up nearly 88%. It has two clinical Alzheimer's candidates, PRX005 and PRX012, both in phase 1. They are antibodies. PRX005 targets tau protein while PRX012 targets amyloid protein.
AC Immune (ACIU) added ~24%. In phase 2, in collaboration with Roche's (OTCQX:RHHBY) Genentech unit, it is developing the anti-tau antibody semorinemab. And in phase 1, in collaboration with Johnson & Johnson's (JNJ) Janssen unit, it has the anti-tau vaccine ACI-35.030.
The one Alzheimer's stock that finished down was Cassava Sciences (SAVA), which has the oral medication simufilam in its pipeline. It closed off 5%.